Real World Study of Lapatinib Among Metastatic Breast Cancer Patients

Real World Study of Lapatinib Among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03894410

Enrollment

242

Registered

2019-03-28

Start date

2019-01-10

Completion date

2020-05-20

Last updated

2024-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

HER2, Lapatinib

Brief summary

A multicenter, retrospective, real world study of Lapatinib among Metastatic Breast Cancer (MBC) Patients in Clinical Practice.

Detailed description

This study collected patients used Lapatinib-base therapy among MBC, and tried to figure out if there was difference between single anti-Her2 treatment and dual anti-Her2 treatment. Furthermore, this study investigated the treatment after Lapatinib.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients who were treated with Lapatinib between June 2014 to June 2018. * Patients experienced progression on prior trastuzumab-containing regimens and a taxane. * Complete medical history was available.

Exclusion criteria

* Medical history was incomplete.

Design outcomes

Primary

Measure	Time frame	Description
PFS	6 weeks	Progression free survival
Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)	6 weeks	—

Countries

China

Outcome results